MiMedx Group Inc (MDXG.OQ)
MDXG.OQ on NASDAQ Stock Exchange Capital Market
7.40USD
23 Apr 2018
7.40USD
23 Apr 2018
Change (% chg)
$-0.10 (-1.33%)
$-0.10 (-1.33%)
Prev Close
$7.50
$7.50
Open
$7.46
$7.46
Day's High
$7.54
$7.54
Day's Low
$7.16
$7.16
Volume
500,682
500,682
Avg. Vol
866,152
866,152
52-wk High
$18.24
$18.24
52-wk Low
$6.05
$6.05
Revenue & Earnings Per Share
Revenue* | Earnings Per Share** | ||
---|---|---|---|
FY 2017 | Sep '17 | 84.57 | 0.149 |
Jun '17 | 76.41 | 0.069 | |
Mar '17 | 72.61 | 0.038 | |
FY 2016 | Dec '16 | 69.88 | 0.048 |
Sep '16 | 64.43 | 0.030 | |
Jun '16 | 57.34 | 0.018 | |
Mar '16 | 53.37 | 0.011 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
# of Estimates | Mean | High | Low | 1 Year Ago | |
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 3 | 92.52 | 94.75 | 90.40 | 86.99 |
Quarter Ending Sep-18 | 3 | 99.43 | 100.60 | 97.09 | 93.27 |
Year Ending Dec-18 | 4 | 384.90 | 387.11 | 381.40 | 360.15 |
Earnings (per share) | |||||
Quarter Ending Jun-18 | 3 | 0.07 | 0.07 | 0.06 | 0.08 |
Quarter Ending Sep-18 | 3 | 0.09 | 0.10 | 0.08 | 0.09 |
Year Ending Dec-18 | 4 | 0.33 | 0.34 | 0.31 | 0.26 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
Company | industry | sector | ||
---|---|---|---|---|
P/E Ratio (TTM) | 24.68 | 35.59 | 33.60 | |
P/E High - Last 5 Yrs. | 210.02 | 41.27 | 45.95 | |
P/E Low - Last 5 Yrs. | 36.16 | 21.23 | 24.93 | |
Beta | 1.56 | 0.75 | 0.80 | |
Price to Sales (TTM) | 2.74 | 7.57 | 7.07 | |
Price to Book (MRQ) | 5.85 | 15.35 | 5.13 | |
Price to Tangible Book (MRQ) | 7.42 | 25.14 | 6.73 | |
Price to Cash Flow (TTM) | 20.29 | 24.66 | 25.52 | |
% Owned Institutions | 83.41 | 4.15 | 2.22 |
Dividends
Company | industry | sector | ||
---|---|---|---|---|
Dividend Yield | -- | 0.88 | 1.51 | |
Dividend Yield - 5 Year Avg | -- | 1.13 | 0.75 | |
Dividend 5 Year Growth Rate | -- | 17.53 | 3.93 | |
Payout Ratio(TTM) | 0.00 | 27.53 | 20.35 |
Growth Rates
Company | industry | sector | ||
---|---|---|---|---|
Sales (MRQ) vs Qtr. 1 Yr. Ago | 31.27 | 14.74 | 9.02 | |
Sales (TTM) vs TTM 1 Yr. Ago | 33.70 | 11.05 | 10.83 | |
Sales - 5 Yr. Growth Rate | 99.46 | 8.90 | 8.21 | |
EPS (MRQ) vs Qtr. 1 Yr. Ago | 402.60 | 80.39 | 22.25 | |
EPS (TTM) vs TTM 1 Yr. Ago | 71.56 | -- | -- | |
EPS - 5 Yr. Growth Rate | -- | 19.77 | 10.26 | |
Capital Spending - 5 Yr. Growth Rate | 71.02 | 9.75 | 10.37 |
Financial Strength
Company | industry | sector | |
---|---|---|---|
Quick Ratio (MRQ) | 2.95 | 2.43 | 2.53 |
Current Ratio (MRQ) | 3.25 | 3.21 | 3.62 |
LT Debt to Equity (MRQ) | 0.00 | 29.05 | 11.31 |
Total Debt to Equity (MRQ) | 0.01 | 33.43 | 13.97 |
Interest Coverage (TTM) | 54.29 | 16.50 | 30.11 |
Profitability Ratios
Company | industry | sector | ||
---|---|---|---|---|
Gross Margin (TTM) | 88.19 | 57.95 | 54.01 | |
Gross Margin - 5 Yr. Avg. | 87.47 | 57.51 | 52.12 | |
EBITD Margin (TTM) | 12.15 | -- | -- | |
EBITD - 5 Yr. Avg | 9.10 | 22.99 | 15.89 | |
Operating Margin (TTM) | 11.61 | 19.12 | 4.33 | |
Operating Margin - 5 Yr. Avg. | 6.58 | 15.65 | 11.25 | |
Pre-Tax Margin (TTM) | 11.47 | 18.73 | 4.97 | |
Pre-Tax Margin - 5 Yr. Avg. | 5.93 | 15.80 | 11.56 | |
Net Profit Margin (TTM) | 11.64 | 14.51 | 1.58 | |
Net Profit Margin - 5 Yr. Avg. | 5.63 | 10.93 | 7.89 | |
Effective Tax Rate (TTM) | -1.51 | 20.98 | 31.30 | |
Effective Tax Rate - 5 Yr. Avg. | 5.02 | 28.80 | 24.27 |
Efficiency
Company | industry | sector | ||
---|---|---|---|---|
Revenue/Employee (TTM) | 439,809 | 29,048,791 | 816,988,634 | |
Net Income/Employee (TTM) | 51,209 | 3,716,463 | 96,050,323 | |
Receivable Turnover (TTM) | 4.93 | 4.90 | 5.56 | |
Inventory Turnover (TTM) | 2.49 | 3.00 | 3.45 | |
Asset Turnover (TTM) | 1.68 | 0.75 | 0.89 |
Management Effectiveness
Company | industry | sector | ||
---|---|---|---|---|
Return on Assets (TTM) | 19.61 | 10.67 | 10.54 | |
Return on Assets - 5 Yr. Avg. | 7.55 | 8.90 | 11.56 | |
Return on Investment (TTM) | 24.92 | 14.13 | 13.19 | |
Return on Investment - 5 Yr. Avg. | 9.25 | 11.62 | 14.97 | |
Return on Equity (TTM) | 26.59 | 16.91 | 15.00 | |
Return on Equity - 5 Yr. Avg. | 9.87 | 14.09 | 16.25 |
1 Year | 3 Year | 5 Year | |
---|---|---|---|
Sales % | 30.82 | 60.57 | 99.46 |
EPS (TTM) % | -58.91 | -- | -- |
Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for MiMedx Group Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of Amniofix® Injectable For Treatment Of Osteoarthritis Of The Knee
- BRIEF-Mimedx Reports Positive Results From Phase 2B Clinical Trial Of Amniofix Injectable
- BRIEF-MiMedx Says "Confident" in Q1 Rev Guidance, Discloses DoJ Investigation
- BRIEF-Mimedx's Amniofix Injectable Granted RMAT Designation By FDA
- BRIEF-MiMedx Receives Notice Of Filing Delinquency From Nasdaq
Institutional Holders
% Shares Owned: | 83.41% |
# of Holders: | 303 |
Total Shares Held: | 92,610,317 |
3 Mo. Net Change: | 2,527,318 |
# New Positions: | 4 |
# Closed Positions: | 5 |
# Increased Positions: | 16 |
# Reduced Positions: | 19 |
# Net Buyers: | -3 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.